Shares of IDEXX Laboratories (IDXX) surged 8.21% in pre-market trading on Thursday after the animal diagnostics company reported better-than-expected first quarter earnings and raised its full-year guidance.
IDEXX posted earnings per share of $2.96 for Q1 2025, surpassing the FactSet analyst consensus estimate of $2.85. Revenue came in at $998.4 million, slightly above analyst expectations of $997.1 million. The company's gross margin expanded to 62.4% from 61.5% in the year-ago quarter, while operating margin improved to 31.7% from 31.0%.
Investors were particularly encouraged by IDEXX's raised outlook for 2025. The company now expects full-year earnings per share of $11.93 to $12.43, up from its previous guidance of $11.74 to $12.24. IDEXX also boosted its revenue growth forecast to 5-8%, with projected revenue of $4.10 billion to $4.21 billion.
The strong results were driven by solid performance across IDEXX's business segments. Companion Animal Group diagnostics recurring revenue, a key metric for the company, grew 4.5% organically. IDEXX's water testing and livestock/poultry diagnostics segments also showed healthy growth. The company's ongoing focus on innovation and expanding its diagnostic offerings continues to drive market share gains in the veterinary sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.